BioSpace News Archive

Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced it has received $1.85 million in net cash proceeds from the sale of approximately $2.0 million of its unused New Jersey net operating losses.

VeeMed, a provider of a Virtual Care as-a-service (VCaaS) for the full continuum of care, and BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company offering a medical-grade Data-as-a-Service (DaaS) platform, today announced its partnership that provides scalable Remote Patient Monitoring

Manasi Sinha Jaiman, M.D., M.P.H., Vice President, Clinical Development at ViaCyte, Inc., a clinical-stage regenerative medicine company, will participate in the World Medical Innovation Forum’s (WMIF) Diabetes: Grand Challenge panel on Thursday, May 20, 2021

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors

IsoPlexis, the leader in functional single-cell proteomics, today announced the appointment of Siddhartha Kadia to its Board of Directors.

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Carrie S. Cox has been named Chairman of the Board of Directors, effective immediately. Paul Manning, the outgoing Chairman, will continue to serve as a Director.

Ashvattha Therapeutics to Present at 2021 Sachs 7 th Annual Digital Immuno-Oncology Innovation Forum

Dyno Therapeutics , a biotechnology company applying artificial intelligence (AI) to gene therapy, will describe ongoing enhancements to its machine learning platform in three oral presentations at the 24th annual meeting of the American Society of Gene and Cell Therapapies

Updated long-term efficacy and safety data of Vitrakvi® (larotrectinib) for patients with TRK fusion cancer from an integrated dataset, sub-analyses for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer, respectively, as well as updated results from an intra-patient comparison to be featured